173 related articles for article (PubMed ID: 35462031)
21. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
22. Role of immunotherapy in stage III nonsmall cell lung cancer.
Wrona A
Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
[TBL] [Abstract][Full Text] [Related]
23. Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
Evison M; Edwards J; McDonald F; Popat S
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):527-536. PubMed ID: 32216979
[TBL] [Abstract][Full Text] [Related]
24. Durvalumab after concurrent chemoradiotherapy in a patient with chemotherapy-resistant unresectable stage III non-small cell lung cancer: a case report.
Zhang T; Wu Y; Zheng S; Cheng G; He X; Bi N
Ann Palliat Med; 2020 Jul; 9(4):2375-2380. PubMed ID: 32692219
[TBL] [Abstract][Full Text] [Related]
25. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy].
Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339
[No Abstract] [Full Text] [Related]
26. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Vrankar M; Stanic K
Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037
[TBL] [Abstract][Full Text] [Related]
27. A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancer.
Wu Y; Guo Z; Meng L; Fan R; Gridelli C; Park HS; Cao Y; Wang L
Transl Lung Cancer Res; 2023 Nov; 12(11):2209-2218. PubMed ID: 38090516
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
29. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
30. Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.
Bruni A; Giaj-Levra N; Ciammella P; Maragna V; Ferrari K; Bonti V; Grossi F; Greco S; Greco C; Borghetti P; Franceschini D; Capelletto E; Perna M; Banna G; Vagge S; Baldini E; Bria E; Botti A; Tiseo M; Paci M; Taraborrelli M; Poletti V; Granone P; Ricardi U; Novello S; Scotti V
PLoS One; 2019; 14(11):e0224027. PubMed ID: 31721773
[TBL] [Abstract][Full Text] [Related]
31. Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.
Cytryn S; Ferreira V; Boland P; Chachoua A; Sabari J
Lung Cancer; 2021 Aug; 158():15-17. PubMed ID: 34091214
[TBL] [Abstract][Full Text] [Related]
32. Treatment Decision Drivers in Stage III Non-Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States.
Cotarla I; Boron ML; Cullen SL; Spinner DS; Faulkner EC; Carroll MC; Shah S; Yagui-Beltran A
JCO Oncol Pract; 2020 Oct; 16(10):e1232-e1242. PubMed ID: 32552457
[TBL] [Abstract][Full Text] [Related]
33. A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.
Varlotto JM; Sun Z; Ky B; Upshaw J; Fitzgerald TJ; Diehn M; Lovly C; Belani C; Oettel K; Masters G; Harkenrider M; Ross H; Ramalingam S; Pennell NA
Clin Lung Cancer; 2022 Nov; 23(7):547-560. PubMed ID: 35882620
[TBL] [Abstract][Full Text] [Related]
34. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.
Botticella A; Mezquita L; Le Pechoux C; Planchard D
Ther Adv Respir Dis; 2019; 13():1753466619885530. PubMed ID: 31686616
[TBL] [Abstract][Full Text] [Related]
35. Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice.
Bonanno L; Attili I; Pavan A; Sepulcri M; Pasello G; Rea F; Guarneri V; Conte P
Crit Rev Oncol Hematol; 2021 Jul; 163():103378. PubMed ID: 34087343
[TBL] [Abstract][Full Text] [Related]
36. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
Davies M; Duffield E
Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679
[TBL] [Abstract][Full Text] [Related]
37. [Role of immunotherapy in locally advanced non-small cell lung cancer].
Levy A; Doyen J; Botticella A; Bourdais R; Achkar S; Giraud P; Du C; Naltet C; Lavaud P; Besse B; Pradère P; Mercier O; Caramella C; Planchard D; Deutsch E; Le Péchoux C
Cancer Radiother; 2020 Feb; 24(1):67-72. PubMed ID: 32037126
[TBL] [Abstract][Full Text] [Related]
38. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
[TBL] [Abstract][Full Text] [Related]
39. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
40. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]